Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Psychiatry Med. 2011;41(1):71-89.

Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double-blind, placebo-controlled trial.

Author information

1
Department of Pediatrics, Nagasaki University Hospital, Japan. kontatsu@nagasaki-u.ac.jp

Abstract

OBJECTIVE:

Down syndrome (DS) patients share certain neuropathological features with Alzheimer disease patients. A randomized, double-blind, placebo-controlled study was performed to investigate the efficacy and safety of donepezil, an Alzheimer disease drug, for DS patients.

METHOD:

Twenty-one DS patients with severe cognitive impairment were assigned to take donepezil (3 mg daily) or a placebo for 24 weeks, and evaluated for activities in daily lives by concisely modified International Classification of Functioning, Disability and Health (ICF) scaling system.

RESULTS:

ICF scores significantly increased without any adverse effects in the donepezil group in comparison to those in the placebo control. Among the individual functions tested, there was a dramatic improvement in the global mental functions and in specific mental functions.

CONCLUSIONS:

Donepezil may effectively and safely improve overall functioning of DS patients with severe cognitive impairment.

PMID:
21495523
DOI:
10.2190/PM.41.1.g
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center